

From June 12, 2026 P&T
Florida Pharmaceutical and Therapeutics Committee
Drug Summary of Changes
Effective 10.01.2026

Changes Effective 10.01.2026	PDL Status Before Meeting	PDL Status After Meeting	Comment
ANTIHYPERTENSIVES, SYMPATHOLYTICS			
JAVADIN SOLUTION (ORAL)	NA	Non-PDL	
ANTIPSYCHOTICS			
ERZOFRI (INTRAMUSCULAR)	Non-PDL	PDL	AUTO PA
PERSIS (SUBCUTANEOUS)	PDL	Non-PDL	
ERYTHROPOIESIS STIMULATING PROTEINS			
RETACRIT (INJECTION)	PDL	Non-PDL	
ESTROGEN AGENTS, ORAL/TRANSDERMAL			
LYNKUET (ORAL)	NA	Non-PDL	
GI MOTILITY, CHRONIC			
MOVANTIK (ORAL)	PDL	Non-PDL	
PRUCALOPRIDE TABLET (ORAL)	Non-PDL	PDL	AUTO PA
GLUCOCORTICOIDS, ORAL			
KHINDIVI SOLUTION (ORAL)	NA	Non-PDL	
GROWTH HORMONE			
SKYTROFA CARTRIDGE (SUBCUTANEOUS)	Non-PDL	PDL	CLINICAL PA
HAE TREATMENTS			
ORLADEYO PELLET PACK (ORAL)	NA	Non-PDL	
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS			
OZEMPIC TABLET (ORAL)	NA	PDL	CLINICAL PA
RYBELSUS (ORAL)	Non-PDL	PDL	CLINICAL PA
HYPOGLYCEMICS, INSULIN AND RELATED AGENTS			
INSULIN LISPRO VIAL (AG) (SUBCUTANEOUS)	PDL	Non-PDL	
NOVOLOG CARTRIDGE (SUBCUTANEOUS)	PDL	Non-PDL	
NOVOLOG PEN (SUBCUTANEOUS)	PDL	Non-PDL	
NOVOLOG VIAL (SUBCUTANEOUS)	PDL	Non-PDL	
HYPOGLYCEMICS, SGLT2			
DAPAGLIFLOZIN (AG) (ORAL)	Non-PDL	PDL	
DAPAGLIFLOZIN (FARXIGA) (ORAL)	Non-PDL	PDL	
FARXIGA (ORAL)	PDL	Non-PDL	
JARDIANCE (ORAL)	Non-PDL	PDL	
SYNJARDY (ORAL)	Non-PDL	PDL	
SYNJARDY XR (ORAL)	Non-PDL	PDL	

IMMUNOMODULATORS, ASTHMA			
EXDENSUR SYRINGE (SUBCUTANEOUS)	NA	Non-PDL	
IMMUNOMODULATORS, ATOPIC DERMATITIS			
VTAMA (TOPICAL)	Non-PDL	PDL	AUTO PA
LIPOTROPICS, OTHER			
REDEMPLO SYRINGE (SUBCUTANEOUS)	NA	Non-PDL	
MULTIPLE SCLEROSIS AGENTS			
BRIUMVI (INTRAVENOUS)	Non-PDL	PDL	
OCREVUS ZUNOVO VIAL (SUBCUTANEOUS)	NA	Non-PDL	
TYRUKO (INTRAVENOUS)	NA	Non-PDL	
ONCOLOGY, INJECTABLE			
ADCETRIS (INTRAVENOUS)	Non-PDL	PDL	CLINICAL PA
ALYMSYS (INTRAVENOUS)	Non-PDL	PDL	AUTO PA
ARSENIC TRIOXIDE (INTRAVENOUS)	Non-PDL	PDL	
BCG (TICE STRAIN) (INTRAVESICAL)	Non-PDL	PDL	
BELEODAQ (INTRAVENOUS)	Non-PDL	PDL	
BIZENGRI VIAL (INTRAVENOUS)	NA	Non-PDL	
BLINCYTO (INTRAVENOUS)	Non-PDL	PDL	CLINICAL PA
BREYANZI (INTRAVENOUS)	Non-PDL	PDL	CLINICAL PA
BUSULFAN (INTRAVENOUS)	Non-PDL	PDL	
CARVYKTI (INTRAVENOUS)	Non-PDL	PDL	CLINICAL PA
DACTINOMYCIN (COSMEGEN) (INTRAVENOUS)	Non-PDL	PDL	
DARZALEX (INTRAVENOUS)	Non-PDL	PDL	
EMRELIS (INTRAVENOUS)	NA	Non-PDL	
ERIBULIN MESYLATE VIAL (INTRAVENOUS)	Non-PDL	PDL	
HERCESSI VIAL (INTRAVENOUS)	Non-PDL	PDL	
IMLYGIC (INJECTION)	Non-PDL	PDL	CLINICAL PA
IXEMPRA (INTRAVENOUS)	Non-PDL	PDL	
KANJINTI (INTRAVENOUS)	Non-PDL	PDL	
KEYTRUDA QLEX (SUBCUTANEOUS)	NA	PDL	
LUNSUMIO VELO VIAL (SUBCUTANEOUS)	NA	Non-PDL	
LYMPHIR VIAL (INTRAVENOUS)	NA	Non-PDL	
LYNOZYFIC (INTRAVENOUS)	NA	Non-PDL	
OPDIVO QVANTIG (SUBCUTANEOUS)	NA	Non-PDL	
RITUXAN (INTRAVENOUS)	Non-PDL	PDL	AUTO PA
RUXIENCE (INTRAVENOUS)	PDL	Non-PDL	
RYBREVANT FASPRO VIAL (SUBCUTANEOUS)	NA	Non-PDL	
SYLVANT (INTRAVENOUS)	Non-PDL	PDL	AUTO PA
TECENTRIQ HYBREZA VIAL (SUBCUTANEOUS)	NA	Non-PDL	
THIOTEPA (INJECTION)	Non-PDL	PDL	
TIVDAK (INTRAVENOUS)	Non-PDL	PDL	CLINICAL PA
TRAZIMERA (INTRAVENOUS)	PDL	Non-PDL	
UNITUXIN (INTRAVENOUS)	Non-PDL	PDL	CLINICAL PA

UNLOXCYT VIAL (INTRAVENOUS)	NA	Non-PDL	
VECTIBIX (INTRAVENOUS)	Non-PDL	PDL	CLINICAL PA
ZIRABEV (INTRAVENOUS)	PDL	Non-PDL	
PAH AGENTS, INJECTABLE			
SILDENAFIL (INTRAVENOUS)	Non-PDL	PDL	AUTO PA
PITUITARY SUPPRESSIVE AGENTS, LHRH			
TRIPTODUR KIT 6-MONTH (INTRAMUSCULAR)	PDL	Non-PDL	
PRENATAL VITAMINS			
CONCEPT DHA (ORAL)	PDL	Non-PDL	
CONCEPT OB (ORAL)	PDL	Non-PDL	
PROVIDA OB (ORAL)	PDL	Non-PDL	
ROSACEA AGENTS, TOPICAL			
METRONIDAZOLE GEL PUMP (AG) (TOPICAL)	Non-PDL	PDL	
SKELETAL MUSCLE RELAXANTS			
ONTRALFY SOLUTION (ORAL)	NA	Non-PDL	
STIMULANTS AND RELATED AGENTS			
LISDEXAMFETAMINE CAPSULE (ORAL)	Non-PDL	PDL	
UREA CYCLE DISORDERS, ORAL			
PHEBURANE (ORAL)	PDL	Non-PDL	

Changes Effective 7.01.2026	PDL Status Before Meeting	PDL Status After Meeting	Comment
CYTOKINE & CAM ANTAGONISTS			
SELARSDI VIAL (INTRAVENOUS)	Non-PDL	PDL	AUTO PA